ENPICOM Secures Funding Round To Finalize IGX Platform Development
ENPICOM SECURES FUNDING ROUND TO FINALIZE IGX PLATFORM DEVELOPMENT BOM Brabant Ventures, NextGen Ventures and [...]
Survey Results: European Immunotherapy Companies Have Great Concerns Regarding Increasing Costs And Long Development Timelines
SURVEY RESULTS: EUROPEAN IMMUNOTHERAPY COMPANIES HAVE GREAT CONCERNS REGARDING INCREASING COSTS AND LONG DEVELOPMENT TIMELINES [...]
ENPICOM sets a new standard for B cell receptor repertoire analysis
ENPICOM SETS A NEW STANDARD FOR B CELL RECEPTOR REPERTOIRE ANALYSIS ‘s-Hertogenbosch, The Netherlands, December [...]
Towards a Predictable Combination Therapy for Multiple Cancer Types
TOWARDS A PREDICTABLE COMBINATION THERAPY FOR MULTIPLE CANCER TYPES Glycostem and [...]
New Scientific Presentation: Accelerate Your Immunotherapy Target Discovery Using Immune Repertoire Sequencing
Accelerate Your Immunotherapy Target Discovery Using Immune Repertoire Sequencing Dr. Nicola Bonzanni, Chief Scientific Officer [...]
ENPICOM Team Wins Microsoft Genomics Hackathon
ENPICOM Team Wins Microsoft Genomics Hackathon The ENPICOM Rockstar team, together with the Biocartis team, [...]
Scientific Poster From UKE/ENPICOM Receives Award at Annual Meeting Of DGHO
Scientific Poster From UKE and ENPICOM Receives Award at Annual Meeting Of DGHO Dr. Donjete [...]
Ronald Burggrave Appointed As Sales Director
Ronald Burggrave Appointed As Sales Director ENPICOM is pleased to announce the appointment of Ronald [...]
ENPICOM Presents at World Immunotherapy Congress 2018
ENPICOM Presents at World Immunotherapy Congress 2018 The World Immunotherapy Congress brings together the pioneers [...]
CSO of ENPICOM Gives Keynote Lecture at ByteMAL Conference 2018
Nicola Bonzanni, CSO of ENPICOM, Gives Keynote Lecture at ByteMAL Conference 2018 Dr. Nicola Bonzanni, [...]